BRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)

Reuters

Jan 12

BRIEF-<a href="https://laohu8.com/S/ATRA">Atara Biotherapeutics</a> Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)

Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:

ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLO™ (TABELECLEUCEL)
ATARA BIOTHERAPEUTICS INC: U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED A COMPLETE RESPONSE LETTER $(CRL)$
ATARA BIOTHERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR EBVALLO BLA
ATARA BIOTHERAPEUTICS INC - FDA UNABLE TO APPROVE EBVALLO BLA IN PRESENT FORM

Source text: ID:nBw3LZs1ca

Further company coverage: ATRA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602510951"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602510951\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602510951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602510951","market":"nz","top_or_hot":-1,"title":"BRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Atara Biotherapeutics Inc <span>ATRA.O</span>:</p><ul><li><p>ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLO™ (TABELECLEUCEL)</p></li><li><p>ATARA BIOTHERAPEUTICS INC: U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED A COMPLETE RESPONSE LETTER <a href=\"https://laohu8.com/S/CRL\">$(CRL)$</a></p></li><li><p>ATARA BIOTHERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR EBVALLO BLA</p></li><li><p>ATARA BIOTHERAPEUTICS INC - FDA UNABLE TO APPROVE EBVALLO BLA IN PRESENT FORM</p></li></ul><p>Source text: <span>ID:nBw3LZs1ca</span></p><p>Further company coverage: <span>ATRA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ATRA\">Atara Biotherapeutics</a> Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Atara Biotherapeutics Inc <span>ATRA.O</span>:</p><ul><li><p>ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLO™ (TABELECLEUCEL)</p></li><li><p>ATARA BIOTHERAPEUTICS INC: U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED A COMPLETE RESPONSE LETTER <a href=\"https://laohu8.com/S/CRL\">$(CRL)$</a></p></li><li><p>ATARA BIOTHERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR EBVALLO BLA</p></li><li><p>ATARA BIOTHERAPEUTICS INC - FDA UNABLE TO APPROVE EBVALLO BLA IN PRESENT FORM</p></li></ul><p>Source text: <span>ID:nBw3LZs1ca</span></p><p>Further company coverage: <span>ATRA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA99RDBT:1","article_id":"2602510951","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602510951","pubTimestamp":1768223116,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo (Tabelecleucel)Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATRA":"Atara Biotherapeutics"},"translate_title":"简介-Atara Biotherapeutics提供Ebvallo的监管和业务更新™（表）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRA":0.9},"content_text":"BRIEF-Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLO™ (TABELECLEUCEL)ATARA BIOTHERAPEUTICS INC: U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED A COMPLETE RESPONSE LETTER $(CRL)$ATARA BIOTHERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR EBVALLO BLAATARA BIOTHERAPEUTICS INC - FDA UNABLE TO APPROVE EBVALLO BLA IN PRESENT FORMSource text: ID:nBw3LZs1caFurther company coverage: ATRA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}